Individualized Neoantigen Specific Immunotherapy, iNeST (Personalized Cancer Vaccine, PCV)

(RG6180)

Melanoma

Phase II

A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

NCT03815058

Solid Tumor

Phase II

A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

NCT03289962

Phase I

A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

NCT03289962